Hybrid viral plasmid and microorganisms containing same
    11.
    发明授权
    Hybrid viral plasmid and microorganisms containing same 失效
    杂交病毒质粒和含有相同的微生物

    公开(公告)号:US4562155A

    公开(公告)日:1985-12-31

    申请号:US496000

    申请日:1983-05-19

    摘要: pML BK is a hybrid plasmid which is constructed of :pML which contains the entire nucleotide sequence of the plasmid pBR322 except for deletion of nucleotide sequences 1120-2490 bp and 0 to 375 bp, and BK which contains the entire nucleotide sequence of the Gardner strain of BK virus except for deletion of nucleotide sequences between bp 5089-5196. Into the pML BK plasmid may be inserted a viral or human gene X to be expressed, an example of which is TK which represents the Bam HI generated 3,600 bp DNA fragment of herpes simplex virus type 1 which contains the herpes simplex virus type 1 TK DNA. The majority of the pML BK X DNA molecules remain in the episomal or free state in the human cells 143B and express the gene X.

    摘要翻译: pML BK是由以下构成的杂交质粒:pML,其含有质粒pBR322的全部核苷酸序列,除了缺失1120-2490bp和0至375bp的核苷酸序列,以及含有加德纳菌株的全部核苷酸序列的BK 的BK病毒,除了bp 5089-5196之间的核苷酸序列的缺失。 可以将pMLBK质粒插入待表达的病毒或人基因X,其实例是表示Bam HI的TK,其产生含有单纯疱疹病毒1型TK DNA的3,600bp的单纯疱疹病毒DNA片段 。 大多数pML BK X DNA分子在人类细胞143B中保持在游离状态或自由状态,并表达基因X.

    Kits and Methods for Assessing the Coenzyme Q Reducing Status of a Patient, Including a Patient Ingesting a Statin
    12.
    发明申请
    Kits and Methods for Assessing the Coenzyme Q Reducing Status of a Patient, Including a Patient Ingesting a Statin 审中-公开
    用于评估患者辅酶Q降低状态的试剂盒和方法,包括患者服用他汀类药物

    公开(公告)号:US20090081683A1

    公开(公告)日:2009-03-26

    申请号:US12236607

    申请日:2008-09-24

    IPC分类号: C12Q1/68

    CPC分类号: C12Q1/6886 C12Q2600/156

    摘要: The disclosure relates to kits and methods for assessing whether an individual is likely to benefit from nutritional supplementation with coenzyme Q and, more particularly, a reduced form of coenzyme Q. The methods involve assessing occurrence of a polymorphism in the gene encoding NQO1 in the individual. Individuals homozygous for the polymorphism will receive optimal benefits from supplementation with the reduced form of coenzyme Q. The disclosure further relates to methods for predicting and assigning a coenzyme Q redox status phenotype based on assessment of an individual's genome for a polymorphism in the gene encoding NQO1.

    摘要翻译: 本公开涉及用于评估个体是否可能从辅酶Q的营养补充中受益的试剂盒和方法,更具体地,减少形式的辅酶Q。所述方法涉及评估个体中编码NQO1的基因中的多态性的发生 。 对于多态性纯合的个体将从补体形式的辅酶Q中获得最佳益处。本发明还涉及基于编码NQO1基因的多态性的个体基因组的评估来预测和分配辅酶Q氧化还原状态表型的方法 。

    Methods for identifying antiviral agents against human herpesviruses
    13.
    发明授权
    Methods for identifying antiviral agents against human herpesviruses 有权
    鉴定人类疱疹病毒抗病毒药物的方法

    公开(公告)号:US06204028B1

    公开(公告)日:2001-03-20

    申请号:US09280766

    申请日:1999-03-29

    IPC分类号: C12P1934

    CPC分类号: C12Q1/18

    摘要: A method of screening compounds for antiviral activity against a selected human herpesvirus by measuring inhibition of DNA synthesis by DNA polymerase and processivity factor of the selected human herpesvirus in the presence of the compound is provided.

    摘要翻译: 提供了通过测定DNA聚合酶的DNA合成抑制和选择的人疱疹病毒在化合物存在下的持续性因子来筛选化合物对选择的人疱疹病毒的抗病毒活性的方法。

    Therapeutic compounds for blocking DNA synthesis of pox viruses
    14.
    发明授权
    Therapeutic compounds for blocking DNA synthesis of pox viruses 有权
    用于阻断痘病毒DNA合成的治疗化合物

    公开(公告)号:US08524719B2

    公开(公告)日:2013-09-03

    申请号:US13590667

    申请日:2012-08-21

    IPC分类号: A61K31/519

    摘要: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

    摘要翻译: 本发明提供了通过使痘病毒与具有式I,式XXI,式XXXII或式XLI的化合物接触来抑制痘病毒复制的方法,其又减少,抑制或消除痘病毒DNA聚合酶活性和/或其与其相互作用 持续性因素 式I,式XXI,式XXXII或式XLI可用于治疗患有痘病毒感染的人和动物。 还提供了用于治疗痘病毒感染的受试者的药物组合物。

    KITS AND METHODS FOR ASSESSING ANTIOXIDANT REQUIREMENT OF A HUMAN
    15.
    发明申请
    KITS AND METHODS FOR ASSESSING ANTIOXIDANT REQUIREMENT OF A HUMAN 审中-公开
    用于评估人类抗氧化剂需求的试剂盒和方法

    公开(公告)号:US20110027776A1

    公开(公告)日:2011-02-03

    申请号:US11909678

    申请日:2006-03-28

    IPC分类号: C12Q1/68 C07C50/02

    摘要: The invention relates to kits and methods for assessing the desirability of supplementing the diet of a human with reduced coenzyme Q (CoQH2). The methods involve assessing occurrence in the human's genome of the NQO1*2 polymorphism of the NQO1 gene. Occurrence of a copy of the polymorphism indicates that the human can benefit from dietary supplementation with CoQH2, and occurrence of two copies (i.e., homozygosity) of the NQO1*2 polymorphism indicates that dietary supplementation with CoQH2 can be especially desirable.

    摘要翻译: 本发明涉及用于评估补充还原型辅酶Q(CoQH2)的人的饮食的期望性的试剂盒和方法。 该方法涉及评估人类基因组中NQO1基因NQO1 * 2多态性的发生情况。 多态性拷贝的发生表明,人可以从CoQH2的膳食补充中受益,并且NQO1 * 2多态性的两个拷贝(即,纯合性)的发生表明可以特别需要膳食补充CoQH2。

    Use of Genetic Information to Detect a Predisposition for Bone Density Conditions
    16.
    发明申请
    Use of Genetic Information to Detect a Predisposition for Bone Density Conditions 审中-公开
    使用遗传信息检测骨密度条件的倾向

    公开(公告)号:US20080311587A1

    公开(公告)日:2008-12-18

    申请号:US12198424

    申请日:2008-08-26

    IPC分类号: C12Q1/68

    摘要: The invention relates to kits and methods for assessing susceptibility of a human to an undesirable bone density condition, such as osteopenia and osteoporosis, and advising appropriate interventions. The methods involve contemporaneously assessing occurrence in the human's genome of a plurality of polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated with bone density regulation and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kits for performing the methods.

    摘要翻译: 本发明涉及用于评估人类对不希望的骨密度状况如骨质减少和骨质疏松症的易感性以及建议适当干预的试剂盒和方法。 所述方法涉及同时评估人类基因组中出现在与骨密度调节相关并且与人类疾病相关的一个或多个基因中的多个多态性(例如,单核苷酸多态性)中的发生。 公开了优选的评估和评分方法,以及用于执行方法的套件。

    Kit for the non-invasive identification and collection of DNA
    17.
    发明授权
    Kit for the non-invasive identification and collection of DNA 失效
    用于非侵入性鉴定和收集DNA的试剂盒

    公开(公告)号:US06291171B1

    公开(公告)日:2001-09-18

    申请号:US09302623

    申请日:1999-04-30

    IPC分类号: C12Q168

    摘要: A non-invasive kit is provided for collecting and transporting DNA specimens from an individual for analysis or study. The kit contains swabs for harvesting DNA cells from the mouths of individuals and corpses. The kit consists of a rectangular panel having a center portion and two hinged members. The center portion is provided with a folded stand with apertures for holding swabs containing the DNA specimens. Bar coded envelopes are also provided for mailing to a depository.

    摘要翻译: 提供非侵入性试剂盒,用于从个体收集和转运DNA标本用于分析或研究。 该试剂盒包含用于从个体和尸体的口中收集DNA细胞的拭子。 该套件包括具有中心部分和两个铰接构件的矩形面板。 中心部分设置有折叠的支架,其具有用于保持含有DNA标本的拭子的孔。 还提供条形码信封,用于邮寄到存放处。